Navigation Links
Amgen Issues Statement on Outcomes of Advisory Committee for Reproductive Health Drugs (ACRHD) Meeting
Date:8/13/2009

cancer therapy results in significant morbidity, and has no currently approved treatments.

Patient safety is Amgen's top priority. Amgen proposed a comprehensive post-marketing surveillance program, including extensions of studies in the osteoporosis and oncology settings in which more than 5,000 patients will be treated with Prolia for up to 10 years, as well as ongoing studies in the advanced cancer setting. In addition, the Company proposed an observational study using healthcare databases that will involve approximately 380,000 women with postmenopausal osteoporosis for up to 5 years.

"Amgen looks forward to collaborating with the FDA to arrive at the best possible approach to make Prolia available to appropriate patients," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen.

The FDA has targeted an Agency action within ten months of the application's submission date, resulting in a Prescription Drug User Fee Act (PDUFA) action date of Oct. 19, 2009.

About Prolia(TM) (denosumab)

Prolia is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (the cells that break down bone). Prolia is being investigated for its potential to inhibit all stages of osteoclast activity through a targeted mechanism. Prolia is being studied in a range of bone loss conditions including postmenopausal osteoporosis and bone loss in patients undergoing hormone ablation for prostate and breast cancer.

In February 2009, the U.S. Food and Drug Administration (FDA) accepted the Biologics License Application (BLA), submitted by Amgen for Prolia for the treatment and prevention of osteoporosis in postmenopausal women and cancer treatment-induced bone loss in women and men receiving hormone therapy for either breast cancer or prostate can
'/>"/>

SOURCE Amgen Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
2. Medarex to Receive Milestone Payment from Amgen
3. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
4. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
5. CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
6. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
7. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
8. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
9. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
10. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... LOUIS , July 11, 2014 /PRNewswire/ ... device company, announced today the positive, cost-effective ... its innovative SPiNPerc™ procedure. The SPiNPerc endobronchial ... of a percutaneous approach to biopsy when ... Hospitals, patients and physicians experience positive financial ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... 2014  BC Technical, the largest nationwide, non-OEM provider ... Inc., a leading provider of Siemens Nuclear Medicine and ... naming BC Technical as the authorized provider of service ... and BC Technical announced today that the two companies ... as the service and systems provider for MiE,s camera ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... 2011 ChromaDex Corporation (OTCBB: CDXC), an innovative ... and ingredients to the dietary supplement, food & ... results for the second quarter of 2011. On ... U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex ...
... NEW YORK, Aug. 11, 2011 Citeline, an Informa ... pharmaceutical clinical trials recently reviewed the findings from the ... July 16-21, 2011, noting that while pharma continues to ... ahead in terms of biomarkers and early warning for ...
Cached Medicine Technology:ChromaDex Announces Financial Results for Second Quarter 2011 2ChromaDex Announces Financial Results for Second Quarter 2011 3ChromaDex Announces Financial Results for Second Quarter 2011 4Global Standardization for Alzheimer's Biomarkers Moves a Major Step Closer to Reality 2
(Date:7/13/2014)... 13, 2014 The report “Micronutrient ... Iron), Form (Chelated & Non Chelated), Application Mode ... Global Trends and Forecast to 2018” defines and ... analysis and forecasting of the global value and ... driving and restraining factors for the global agriculture ...
(Date:7/13/2014)... July 13, 2014 MarketsandMarkets recently ... [3D Modeling; 3D Scanning; 3D rendering; Layout and ... Analysis (2013 - 2018)”, which analyzes and studies ... North America, Western Europe, Eastern Europe, Middle East ... also draws the competitive landscape of the 3D ...
(Date:7/13/2014)... Athletes with a certain genetic make-up are prone ... research presented today at the American Orthopaedic Society for ... marks the first of its kind investigating a genetic ... that occur after a head injury. , “We ... (GT)n genotype were four times more likely to have ...
(Date:7/13/2014)... Recently, MyDressCity.com, one of the most popular ... has released its new range of elegant Quinceanera ... available at discounted prices. Worldwide clients can enjoy this ... the company’s online shop, there are plenty of beautiful ... with great materials. MyDressCity.com’s hot items are prom gowns, ...
(Date:7/13/2014)... 13, 2014 A decreased ability to identify ... and Alzheimer,s disease, while examinations of the eye ... associated with Alzheimer,s, in the brain, according to ... at the Alzheimer,s Association International Conference 2014 (AAIC ... studies, the decreased ability to identify odors was ...
Breaking Medicine News(10 mins):Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 2Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 3Health News:3D Imaging Market Worth $9.82 Billion By 2018 - Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7
... biomaterial, developed at the New Jersey Center for Biomaterials ... bench to field testing in record time. This achievement, ... is the enabling technology behind a coronary stent undergoing ... , Stents are tiny tubes inserted into diseased arteries ...
... of neurotransmitter dopamine , , THURSDAY, Oct. 18 (HealthDay ... the brain that may explain why some people ... difficult situations. , While the research was done ... better treatments for chronic stress, depression and the ...
... Minn. -- Mayo Clinic has clarified the methods of ... blood vessel disease of the brain and spinal cord ... nervous system vasculitis (PCNSV) can best be identified through ... the cerebral arteries), brain biopsy and other laboratory studies. ...
... Oct. 18 The U.S. House,Judiciary Committee Antitrust ... 971,the Community Pharmacy Fairness Act of 2007. The ... that would allow independent pharmacies to,compete fairly and ... (PBMs). In response Bruce Roberts, RPh, National Community,Pharmacists ...
... ReBuilder,Medical Technologies, Inc. (Pink Sheets: RBRM), an ... device inventor David B.,Phillips, Ph.D., today announced ... facilitation. (Logo: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO ) ... are outsourcing customer service to,overseas facilities, the ...
... Preventive Medical Exams; New Women,s Health ... Texas, Oct. 18 Signaling the next phase ... residential,community under development in McKinney, the Cooper Clinic ... "Father of aerobics" Dr. Kenneth Cooper, who,founded Cooper ...
Cached Medicine News:Health News:Rutgers biomaterial debuts in clinical trials of new stent 2Health News:Rutgers biomaterial debuts in clinical trials of new stent 3Health News:Vulnerability to Stress Linked to Brain Molecule 2Health News:Vulnerability to Stress Linked to Brain Molecule 3Health News:Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord 2Health News:Mayo Clinic clarifies diagnosis for serious blood vessel disease of brain and spinal cord 3Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 2Health News:ReBuilder Medical Technologies, Inc. Hires Nurses Exclusively to Provide Customer Support 3Health News:Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney 2Health News:Cooper Clinic at Craig Ranch Opens Signaling the Next Phase of CooperLife Health-Focused Residential Community in McKinney 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: